AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
(in millions, except per share data) | Quarter Ended June 30, 2023 | Full-Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q2 2023 acquired IPR&D and milestones expense | $ | — | $ | 2.90 | $ | 3.00 | $ | 150 | $ | 10.72 | $ | 11.12 | |||||||||||||||||||||||
Q2 2023 acquired IPR&D and milestones expense | 280 | (0.15) | (0.15) | 280 | (0.15) | (0.15) | |||||||||||||||||||||||||||||
Guidance including Q2 2023 acquired IPR&D and milestones expensea | $ | 280 | $ | 2.75 | $ | 2.85 | $ | 430 | $ | 10.57 | $ | 10.97 |
a The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2023, as both cannot be reliably forecasted.
1